Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection

J. D. Zeuli, S. K. Adie, Stacey Rizza, Zelalem Temesgen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Daclatasvir is a nonstructural protein 5A inhibitor of hepatitis C virus (HCV) replication. Asunaprevir is an NS3/4A complex inhibitor of HCV replication. The combination of daclatasvir and asunaprevir has been approved in Japan for the treatment of genotype 1 chronic HCV infection. In vitro studies have documented potent activity of these drugs, individually and in combination, against genotype 1 HCV. Results from completed and ongoing clinical studies have confirmed this potent activity in patients, with better responses noted in genotype 1b patients compared to patients with genotype 1a HCV. Response rates are also better in treatment-naive patients compared to those who are treatment-experienced; in these cases, the addition of interferon and ribavirin appears to enhance the treatment response. The combination of daclatasvir and asunaprevir is, in general, well tolerated. Daclatasvir and asunaprevir are substrates for cytochrome P450 3A4 enzymatic path- way; thus, there is a substantial potential for drug interactions.

Original languageEnglish (US)
Pages (from-to)629-643
Number of pages15
JournalDrugs of Today
Volume51
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Genotype
Virus Replication
Cytochrome P-450 CYP3A
Ribavirin
Therapeutics
Hepatitis C
Drug Interactions
Interferons
Japan
BMS-790052
asunaprevir
Pharmaceutical Preparations
Proteins

Keywords

  • Asunaprevir
  • BMS-650032
  • Daclatasvir
  • HCV NS3 protease inhibitors
  • Hepatitis C

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection. / Zeuli, J. D.; Adie, S. K.; Rizza, Stacey; Temesgen, Zelalem.

In: Drugs of Today, Vol. 51, No. 11, 01.11.2015, p. 629-643.

Research output: Contribution to journalArticle

@article{2510e6228f3d49f6abae7411e2ad463f,
title = "Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection",
abstract = "Daclatasvir is a nonstructural protein 5A inhibitor of hepatitis C virus (HCV) replication. Asunaprevir is an NS3/4A complex inhibitor of HCV replication. The combination of daclatasvir and asunaprevir has been approved in Japan for the treatment of genotype 1 chronic HCV infection. In vitro studies have documented potent activity of these drugs, individually and in combination, against genotype 1 HCV. Results from completed and ongoing clinical studies have confirmed this potent activity in patients, with better responses noted in genotype 1b patients compared to patients with genotype 1a HCV. Response rates are also better in treatment-naive patients compared to those who are treatment-experienced; in these cases, the addition of interferon and ribavirin appears to enhance the treatment response. The combination of daclatasvir and asunaprevir is, in general, well tolerated. Daclatasvir and asunaprevir are substrates for cytochrome P450 3A4 enzymatic path- way; thus, there is a substantial potential for drug interactions.",
keywords = "Asunaprevir, BMS-650032, Daclatasvir, HCV NS3 protease inhibitors, Hepatitis C",
author = "Zeuli, {J. D.} and Adie, {S. K.} and Stacey Rizza and Zelalem Temesgen",
year = "2015",
month = "11",
day = "1",
doi = "10.1358/dot.2015.51.11.2414528",
language = "English (US)",
volume = "51",
pages = "629--643",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection

AU - Zeuli, J. D.

AU - Adie, S. K.

AU - Rizza, Stacey

AU - Temesgen, Zelalem

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Daclatasvir is a nonstructural protein 5A inhibitor of hepatitis C virus (HCV) replication. Asunaprevir is an NS3/4A complex inhibitor of HCV replication. The combination of daclatasvir and asunaprevir has been approved in Japan for the treatment of genotype 1 chronic HCV infection. In vitro studies have documented potent activity of these drugs, individually and in combination, against genotype 1 HCV. Results from completed and ongoing clinical studies have confirmed this potent activity in patients, with better responses noted in genotype 1b patients compared to patients with genotype 1a HCV. Response rates are also better in treatment-naive patients compared to those who are treatment-experienced; in these cases, the addition of interferon and ribavirin appears to enhance the treatment response. The combination of daclatasvir and asunaprevir is, in general, well tolerated. Daclatasvir and asunaprevir are substrates for cytochrome P450 3A4 enzymatic path- way; thus, there is a substantial potential for drug interactions.

AB - Daclatasvir is a nonstructural protein 5A inhibitor of hepatitis C virus (HCV) replication. Asunaprevir is an NS3/4A complex inhibitor of HCV replication. The combination of daclatasvir and asunaprevir has been approved in Japan for the treatment of genotype 1 chronic HCV infection. In vitro studies have documented potent activity of these drugs, individually and in combination, against genotype 1 HCV. Results from completed and ongoing clinical studies have confirmed this potent activity in patients, with better responses noted in genotype 1b patients compared to patients with genotype 1a HCV. Response rates are also better in treatment-naive patients compared to those who are treatment-experienced; in these cases, the addition of interferon and ribavirin appears to enhance the treatment response. The combination of daclatasvir and asunaprevir is, in general, well tolerated. Daclatasvir and asunaprevir are substrates for cytochrome P450 3A4 enzymatic path- way; thus, there is a substantial potential for drug interactions.

KW - Asunaprevir

KW - BMS-650032

KW - Daclatasvir

KW - HCV NS3 protease inhibitors

KW - Hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=84953323816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953323816&partnerID=8YFLogxK

U2 - 10.1358/dot.2015.51.11.2414528

DO - 10.1358/dot.2015.51.11.2414528

M3 - Article

C2 - 26744738

AN - SCOPUS:84953323816

VL - 51

SP - 629

EP - 643

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 11

ER -